Capello A - Search Results

1

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M. Breeman WA, et al. Among authors: capello a. Int J Cancer. 2003 Apr 10;104(3):376-9. doi: 10.1002/ijc.10952. Int J Cancer. 2003. PMID: 12569562

2

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M. Melis M, et al. Among authors: capello a. Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33. Q J Nucl Med Mol Imaging. 2007. PMID: 17923824 Free article.

3

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Capello A, et al. J Nucl Med. 2003 Jan;44(1):98-104. J Nucl Med. 2003. PMID: 12515882 Free article.

4

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Capello A, et al. Cancer Biother Radiopharm. 2003 Oct;18(5):761-8. doi: 10.1089/108497803770418300. Cancer Biother Radiopharm. 2003. PMID: 14629824

5

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Bernard B, et al. Among authors: capello a. Cancer Biother Radiopharm. 2004 Apr;19(2):173-80. doi: 10.1089/108497804323071940. Cancer Biother Radiopharm. 2004. PMID: 15186597

6

Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

Verwijnen S, Capello A, Bernard B, van den Aardweg G, Konijnenberg M, Breeman W, Krenning E, de Jong M. Verwijnen S, et al. Among authors: capello a. Cancer Biother Radiopharm. 2004 Jun;19(3):285-92. doi: 10.1089/1084978041425098. Cancer Biother Radiopharm. 2004. PMID: 15285875

7

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Capello A, et al. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. doi: 10.1007/s00259-005-1877-x. Epub 2005 Jul 15. Eur J Nucl Med Mol Imaging. 2005. PMID: 16021448

8

Anticancer activity of targeted proapoptotic peptides.

Capello A, Krenning EP, Bernard BF, Breeman WA, Erion JL, de Jong M. Capello A, et al. J Nucl Med. 2006 Jan;47(1):122-9. J Nucl Med. 2006. PMID: 16391196 Free article.

9

Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.

Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M. Capello A, et al. J Nucl Med. 2004 Oct;45(10):1716-20. J Nucl Med. 2004. PMID: 15471839 Free article.

10

Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.

Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen MP. Hofland LJ, et al. Among authors: capello a. J Nucl Med. 2005 Jan;46 Suppl 1:191S-8S. J Nucl Med. 2005. PMID: 15653669 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters